AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29016734 — intervention group
Group type: COMPARATOR
Intervention: Intraoral and panoramic radiography (M1)
Number of subjects: 112
Study 29016734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone Beam CT and panoramic radiography (M2)
Number of subjects: 112
Study 26897130 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling session
Number of subjects: 561
Study 26897130 — intervention group
Group type: COMPARATOR
Intervention: Standard of care counseling session
Number of subjects: 561
Study 26897130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enhanced and standard counseling sessions
Number of subjects: 561
Study 25690407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic treatment
Number of subjects: 70
Study 24136138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified training (n = 13)
Number of subjects: 21
Study 24136138 — intervention group
Group type: COMPARATOR
Intervention: Normal training (n = 8)
Number of subjects: 21
Study 20504977 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased glycemic load test foods
Number of subjects: 15
Study 20504977 — intervention group
Group type: COMPARATOR
Intervention: Decreased glycemic load test foods
Number of subjects: 15
Study 18398365 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold infrared laser (810 nm)
Number of subjects: 20
Study 18398365 — intervention group
Group type: COMPARATOR
Intervention: Conventional macular laser (fellow eye)
Number of subjects: 20
Study 15717460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with fentanyl 2.2 microg/ml
Number of subjects: 36
Study 15717460 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125%
Number of subjects: 36
Study 15717460 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 36
Study 12707429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (600 mg/day for creatinine clearance > 60 mL/min or 300 mg/day for creatinine clearance 30 to 60 mL/min)
Number of subjects: 173
Study 12707429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 173
Study 12707429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 10658522 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of mastectomy in the follicular phase
Number of subjects: 721
Study 10658522 — intervention group
Group type: COMPARATOR
Intervention: Timing of mastectomy in the luteal phase
Number of subjects: 721
Study 8665064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101)
Number of subjects: 191
Study 8665064 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90)
Number of subjects: 191
Study 1987228 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion (16 ng/kg per min)
Number of subjects: 8
Study 1987228 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion
Number of subjects: 8
Study 6342165 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC plus 1 g ascorbic acid (Redoxon) daily for 6 months
Number of subjects: 16
Study 6342165 — intervention group
Group type: COMPARATOR
Intervention: Standard anti‐asthma chemoprophylaxis (SAC)
Number of subjects: 16
Study 6342165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g intravenous injection)
Number of subjects: 16
Study 30139712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 16
Study 30139712 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 16
Study 29563289 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc monotherapy
Number of subjects: 20
Study 26772807 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues (AI) - insulin detemir and insulin aspart
Number of subjects: 109
Study 26772807 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI) - NPH-insulin and regular HI
Number of subjects: 109
Study 24910870 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl retinoate-loaded dissolving microneedle patches
Number of subjects: 24
Study 24910870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid-loaded dissolving microneedle patches
Number of subjects: 24
Study 22834992 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis
Number of subjects: 51
Study 22834992 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Number of subjects: 51
Study 20218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided use with worksheets
Number of subjects: 0
Study 20218830 — intervention group
Group type: COMPARATOR
Intervention: Self-directed use
Number of subjects: 0
Study 20218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomy special study module (dissection of the digestive system)
Number of subjects: 0
Study 20218830 — intervention group
Group type: COMPARATOR
Intervention: Other students (not in the special study module)
Number of subjects: 0
Study 17464379 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at levels of 0 cm H2O, 2 cm H2O, 4 cm H2O, 6 cm H2O, 8 cm H2O, and 10 cm H2O
Number of subjects: 11
Study 17464379 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 11
Study 16312171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% olopatadine nasal spray
Number of subjects: 677
Study 16312171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% olopatadine nasal spray
Number of subjects: 677
Study 16312171 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 677
Study 12393661 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 186
Study 12393661 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 186
Study 10214857 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 83
Study 10214857 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation (APSCT)
Number of subjects: 83
Study 10214857 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT or APSCT
Number of subjects: 83
Study 10214857 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 83
Study 8657828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol [Estraderm TTS (ETTS) 50 micrograms, applied twice weekly]
Number of subjects: 69
Study 8657828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 2229462 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 99
Study 2229462 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 99
Study 2229462 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 99
Study 2229462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol (2.0 mg tablets)
Number of subjects: 0
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg tablets)
Number of subjects: 0
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (1 mg tablets)
Number of subjects: 0
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol (200 mg aerosol)
Number of subjects: 0
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 mg aerosol)
Number of subjects: 0
Study 358427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (200 mg aerosol)
Number of subjects: 0
Study 31851111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Cellular Bone Matrix (ACBM)
Number of subjects: 0
Study 31851111 — intervention group
Group type: COMPARATOR
Intervention: Autologous Bone Graft
Number of subjects: 0
Study 28838469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (double‐blinded, placebo‐controlled crossover)
Number of subjects: 19
Study 28838469 — intervention group
Group type: COMPARATOR
Intervention: Threat-induced anxiety
Number of subjects: 19
Study 25668261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (37.5 mg of elemental iron) daily for 24 weeks (168 days)
Number of subjects: 215
Study 25668261 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 215
Study 24170325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 20
Study 24170325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Referential communication training
Number of subjects: 20
Study 22420121 — intervention group
Group type: COMPARATOR
Intervention: Communicative game (untrained group)
Number of subjects: 20
Study 19414968 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.6 mg/kg
Number of subjects: 30
Study 19414968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg plus nitrous oxide-oxygen inhalation
Number of subjects: 30
Study 17705833 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal computer and fast Internet access at home (Intervention group)
Number of subjects: 123
Study 17705833 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 123
Study 15897444 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stent placement
Number of subjects: 46
Study 15897444 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic agents alone
Number of subjects: 46
Study 12070114 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 297
Study 10463803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics with social phobia
Number of subjects: 794
Study 10463803 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics without social phobia
Number of subjects: 794
Study 7617495 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel
Number of subjects: 46
Study 7617495 — intervention group
Group type: COMPARATOR
Intervention: APF foam
Number of subjects: 46
Study 7617495 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel and foam
Number of subjects: 46
Study 2533187 — intervention group
Group type: EXPERIMENTAL
Intervention: COP 1 treatment
Number of subjects: 0
Study 2533187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 972133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent work at 28 degrees C (45% rh)
Number of subjects: 7
Study 972133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent work at 35 degrees C (65% rh)
Number of subjects: 7
Study 972133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent work at 48 degrees C (10% rh)
Number of subjects: 7
Study 31174403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 1000 mg calcium and 800 IU cholecalciferol
Number of subjects: 100
Study 31174403 — intervention group
Group type: COMPARATOR
Intervention: Group B: 1000 mg calcium and 800 IU cholecalciferol with an additional 1 ml liquid cholecalciferol (50,000 IU) monthly
Number of subjects: 100
Study 28129574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 171
Study 28129574 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 171
Study 28129574 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 171
Study 26545275 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Balance POWERUP
Number of subjects: 24
Study 26545275 — intervention group
Group type: EXPERIMENTAL
Intervention: Under Armour ArmourBite
Number of subjects: 24
Study 26545275 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom mouthguard
Number of subjects: 24
Study 26545275 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard (control)
Number of subjects: 24
Study 23588240 — intervention group
Group type: EXPERIMENTAL
Intervention: True-elimination diet + topical nifedipine and lidocaine
Number of subjects: 161
Study 23588240 — intervention group
Group type: COMPARATOR
Intervention: Sham-elimination diet + topical nifedipine and lidocaine
Number of subjects: 161
Study 23588240 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPC challenge with cow's milk
Number of subjects: 161
Study 23588240 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPC challenge with wheat
Number of subjects: 161
Study 23588240 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reacted to challenges
Number of subjects: 161
Study 21439030 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (n = 16)
Number of subjects: 48
Study 21439030 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (n = 16)
Number of subjects: 48
Study 21439030 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard guidelines) (n = 16)
Number of subjects: 48
Study 21439030 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 48
Study 20133266 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir 1400 mg/100 mg once daily
Number of subjects: 214
Study 20133266 — intervention group
Group type: COMPARATOR
Intervention: fosamprenavir/ritonavir 700 mg/100 mg twice daily
Number of subjects: 214
Study 15618599 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98
Study 15618599 — intervention group
Group type: COMPARATOR
Intervention: Stretching (sham exercise)
Number of subjects: 98
Study 15618599 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (8 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Number of subjects: 160
Study 10360370 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone (7 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Number of subjects: 160
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged < 70 years
Number of subjects: 160
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged >= 70 years
Number of subjects: 160
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day) following induction
Number of subjects: 160
Study 10360370 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF following induction
Number of subjects: 160
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 160
Study 10360370 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 160
Study 8706174 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Chongqing Glaxo Limited (Group A)
Number of subjects: 204
Study 8706174 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Glaxo UK (Group B)
Number of subjects: 204
Study 8706174 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 204
Study 2384652 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 20
Study 2384652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6122463 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg oxprenolol
Number of subjects: 5
Study 6122463 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol
Number of subjects: 5
Study 6122463 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide
Number of subjects: 5
Study 6122463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30943910 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (betamethasone 12 mg, 3 mL intramuscularly)
Number of subjects: 0
Study 30943910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 3 mL IM)
Number of subjects: 0
Study 28531883 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 253
Study 28531883 — intervention group
Group type: COMPARATOR
Intervention: c-TBNA
Number of subjects: 253
Study 28531883 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged strategy (c-TBNA followed by EBUS-TBNA if inconclusive)
Number of subjects: 253
Study 26926544 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical section of the filum plus medical treatment
Number of subjects: 21
Study 26926544 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 21
Study 24354651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis every 3 months
Number of subjects: 52
Study 24354651 — intervention group
Group type: COMPARATOR
Intervention: Control group (without T2DM)
Number of subjects: 52
Study 24354651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Number of subjects: 52
Study 23001587 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773
Number of subjects: 0
Study 23001587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18973910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulating surface projection zone of decussation of pyramid and traditional acupuncture treatment
Number of subjects: 131
Study 18973910 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture treatment only
Number of subjects: 131
Study 17316441 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 0
Study 17316441 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 0
Study 15527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 0
Study 15527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose administration
Number of subjects: 0
Study 15527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose administration
Number of subjects: 0
Study 15527071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11199947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 130
Study 11199947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 11199947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (any dosage)
Number of subjects: 130
Study 9647683 — intervention group
Group type: EXPERIMENTAL
Intervention: I targets (letters 'I')
Number of subjects: 32
Study 9647683 — intervention group
Group type: EXPERIMENTAL
Intervention: O targets (letters 'O')
Number of subjects: 32
Study 8004839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 8004839 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 8004839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and HCTZ
Number of subjects: 0
Study 30075491 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg oral tablets
Number of subjects: 0
Study 30075491 — intervention group
Group type: COMPARATOR
Intervention: Acupressure on foot acupoints (KI-1) for 6 minutes
Number of subjects: 0
Study 28327195 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist group (group A)
Number of subjects: 80
Study 28327195 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 80
Study 25665096 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV and AIDSVAX B/E vaccination
Number of subjects: 0
Study 23532807 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand(®)
Number of subjects: 112
Study 23532807 — intervention group
Group type: COMPARATOR
Intervention: Sleeper One(®)
Number of subjects: 112
Study 21961470 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 5477
Study 21961470 — intervention group
Group type: COMPARATOR
Intervention: Written reminders (Control)
Number of subjects: 5477
Study 19413407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0
Study 19413407 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 17892999 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (3 glasses daily for 6 months)
Number of subjects: 31
Study 17892999 — intervention group
Group type: COMPARATOR
Intervention: Water (control group, 3 glasses daily for 6 months)
Number of subjects: 31
Study 14706203 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol treatment
Number of subjects: 18
Study 14706203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 11685384 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 17
Study 11685384 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 17
Study 11685384 — intervention group
Group type: COMPARATOR
Intervention: Clozapine and Olanzapine
Number of subjects: 17
Study 9597025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary feedback report at baseline plus brief educational materials
Number of subjects: 296
Study 9597025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback report at baseline)
Number of subjects: 296
Study 7888293 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 20
Study 3211661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective eyewear (various models)
Number of subjects: 64
Study 3211661 — intervention group
Group type: COMPARATOR
Intervention: No eyewear (control)
Number of subjects: 64
Study 31313547 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once daily for 4 months along with erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis
Number of subjects: 30
Study 31313547 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis without atorvastatin for 4 months
Number of subjects: 30